Expressive Helping for Malignancies

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
New York University, New York, NY
Malignancies
Expressive Helping - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new intervention to help Chinese American cancer survivors. The intervention is called Expressive Helping (EH). The trial will test if this intervention is feasible and effective. The aim of the trial is to test the efficacy of Expressive Helping in treating patients with malignancies. All patients enrolled in the trial will receive the active treatment, and there will be no placebo group. This is because the drug has already been shown to be effective in treating a different condition and has been approved by the FDA for this use.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up

Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Changes in anxiety symptoms assessed by the Generalized Anxiety Disorder Screener
Changes in cancer-related fatigue assessed by the Functional Assessment of Chronic Illness Therapy - Fatigue
Changes in depressive symptoms assessed by the Center for Epidemiologic Studies Depression Scale
Changes in health-related quality of life assessed by the Functional Assessment of Cancer Therapy: General (FACT-G).
Changes in perceived stress assessed by the Perceived Stress Scale.
Month 6
Completion rate of writing sessions
Recruitment rates
Retention rates

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Factual Writing
1 of 3
Expressive Writing
1 of 3
Expressive Helping
1 of 3
Active Control
Experimental Treatment

108 Total Participants · 3 Treatment Groups

Primary Treatment: Expressive Helping · No Placebo Group · N/A

Expressive Helping
Behavioral
Experimental Group · 1 Intervention: Expressive Helping · Intervention Types: Behavioral
Factual Writing
Behavioral
ActiveComparator Group · 1 Intervention: Factual Writing · Intervention Types: Behavioral
Expressive Writing
Behavioral
ActiveComparator Group · 1 Intervention: Expressive Writing · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Expressive Helping
2019
N/A
~130

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Closest Location: New York University · New York, NY
Photo of New York 1Photo of New York 2Photo of New York 3
2002First Recorded Clinical Trial
2 TrialsResearching Malignancies
108 CompletedClinical Trials

Who is running the clinical trial?

National Institute on Minority Health and Health Disparities (NIMHD)NIH
266 Previous Clinical Trials
449,308 Total Patients Enrolled
4 Trials studying Malignancies
5,922 Patients Enrolled for Malignancies
New York UniversityLead Sponsor
198 Previous Clinical Trials
299,584 Total Patients Enrolled
3 Trials studying Malignancies
2,540 Patients Enrolled for Malignancies

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have had a first cancer diagnosis of stages I-III.
You are able to read and write Simplified or Traditional Chinese.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.